SCHEMBL1784059

SCHEMBL1784059

CC(Oc1ccc(C(=O)O)cc1C(CCN(C(C)C)C(C)C)c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.55
CHRM1 P11229 3/20 0.55
CHRM5 P08912 2/20 0.50
CHRM3 P20309 2/20 0.50
HRH1 P35367 2/20 0.50
ADRB2 P07550 1/20 0.50
CX3CR1 P49238 1/20 0.50
TMEM97 Q5BJF2 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
LMNA P02545 1/20 0.48
ESR1 P03372 1/20 0.48
CHRM4 P08173 1/20 0.48
MAPT P10636 1/20 0.48
KCNE1 P15382 1/20 0.48
PTGS1 P23219 1/20 0.48
HRH2 P25021 1/20 0.48
HTR2A P28223 1/20 0.48
SLC6A4 P31645 1/20 0.48
ADRA1A P35348 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1115911 0.85 CHRM2 (0.75) CHRM2CHRM1CHRM5CHRM3HRH1
SCHEMBL724699 0.85 CHRM2 (0.75) CHRM2CHRM1CHRM5CHRM3HRH1
SCHEMBL19982589 0.85 CHRM2 (0.54) CHRM2CHRM1CHRM5CHRM3HRH1
SCHEMBL723428 0.84 CHRM2 (0.56) CHRM2CHRM1CHRM5CHRM3HRH1
SCHEMBL1783715 0.84 CHRM2 (0.56) CHRM2CHRM1CHRM5CHRM3HRH1
SCHEMBL11292330 0.84 CHRM2 (0.58) CHRM2CHRM1CHRM5CHRM3HRH1
SCHEMBL11297071 0.84 CHRM2 (0.58) CHRM2CHRM1CHRM5CHRM3HRH1
SCHEMBL12653964 0.84 CHRM2 (0.53) CHRM2CHRM1CHRM5CHRM3HRH1
Hydrochloric Acid SCHEMBL597394 0.84 CHRM2 (0.55) CHRM2CHRM1CHRM5CHRM3HRH1
Hydrochloric Acid SCHEMBL597393 0.84 CHRM2 (0.55) CHRM2CHRM1CHRM5CHRM3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124903-A1 SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2011-05-26 US claimed
US-20110124903-A1 SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES ACTAVIS GROUP PTC EHF (IS) 2011-05-26 US disclosed
US-20100217034-A1 Process for the Preparation of Fesoterodine ACTAVIS GROUP PTC EHF (IS) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100217034-A1 Process for the Preparation of Fesoterodine ADRB3, FES, QDPR CHRM2 107/4885CHRM1 279/4885CHRM5 111/4885
US-20110124903-A1 SOLID STATE FORMS OF FESOTERODINE INTERMEDIATES FES, NISCH, RPS27A CHRM2 530/4885CHRM1 646/4885CHRM5 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.